{rfName}
Ev

Indexed in

License and use

Icono OpenAccess

Citations

1

Altmetrics

Analysis of institutional authors

Loscertales JAuthorMuñoz-Calleja CCorresponding Author

Share

August 14, 2023
Publications
>
Article

Evaluation of the novel therapeutic anti-CCR7 antibody CAP-100 as an add-on therapy in chronic lymphocytic leukemia patients receiving venetoclax

Publicated to:HEMATOLOGICAL ONCOLOGY. 41 (5): 869-876 - 2023-12-01 41(5), DOI: 10.1002/hon.3213

Authors: Mateu-Albero, T; Marcos-Jimenez, A; Delgado-Wicke, P; Terron, F; Loscertales, J; Lopez-Matencio, JMS; Munoz-Calleja, C; Cuesta-Mateos, C

Affiliations

Catapult Therapeut, Lelystad, Netherlands - Author
Hosp Univ La Princesa, Hematol Dept, Inst Invest Sanitaria Inst Princesa IIS IP, Madrid, Spain - Author
Hosp Univ La Princesa, Immunol Dept, Inst Invest Sanitaria Inst Princesa IIS IP, Madrid, Spain - Author
Hosp Univ La Princesa, Pharm Dept, Inst Invest Sanitaria Inst Princesa IIS IP, Madrid, Spain - Author
IMMED S.L. - Author
IMMED S.L. , Catapult Therapeutics - Author
IMMED SL, Immunol & Med Prod, C Velazquez 57,6 Derecha, Madrid 28001, Spain - Author
IMMED SL, Immunol & Med Prod, Madrid, Spain - Author
Instituto de Investigación Sanitaria Hospital Universitario de La Princesa - Author
Instituto de Investigación Sanitaria Hospital Universitario de La Princesa , IMMED S.L. , Catapult Therapeutics - Author
Instituto de Investigación Sanitaria Hospital Universitario de La Princesa , Universidad Autónoma de Madrid - Author
Univ Autonoma Madrid, Med Fac, Immunol Dept, Madrid, Spain - Author
See more

Abstract

The Bruton's tyrosine kinase inhibitor ibrutinib and the B-cell lymphoma 2 anti-apoptotic protein inhibitor venetoclax provide high response rates in chronic lymphocytic leukemia (CLL). However, there is a growing number of patients that relapse after treatment or show refractory disease, thus new targets and agents are still needed. We have previously reported the chemokine receptor CCR7 as a relevant deregulated target in CLL and have developed CAP-100, a novel therapeutic anti-CCR7 antibody that is under evaluation for relapse/refractory CLL (NCT04704323). While CCR7 expression has been shown to be down-modulated in CLL patients treated with ibrutinib, whether venetoclax acts in a similar manner remains unaddressed. Here, we aimed to document the impact of venetoclax on CCR7 expression in CLL cells, as well as on the pre-clinical activity of CAP-100. To this end, we addressed CCR7 expression by flow cytometry and the antibody efficacy by means of in vitro chemotactic and antibody-dependent cell-mediated cytotoxicity (ADCC) assays. Our data indicate that venetoclax treatment did not significantly modify CCR7 expression pattern nor CAP-100 mechanisms of action. Together, these findings support CAP-100 as an adjuvant therapy to venetoclax that may introduce additional modes of action in CLL therapy.

Keywords

antibodyb-cell receptorbcl-2cap-100ccr7cd20cllcxcr4expressioninhibitorsligandsmigrationresistancevenetoclaxAntibodyBcl-2Cap-100Ccr7CllImpair antitumor-activityVenetoclax

Quality index

Bibliometric impact. Analysis of the contribution and dissemination channel

The work has been published in the journal HEMATOLOGICAL ONCOLOGY due to its progression and the good impact it has achieved in recent years, according to the agency WoS (JCR), it has become a reference in its field. In the year of publication of the work, 2023, it was in position 30/97, thus managing to position itself as a Q2 (Segundo Cuartil), in the category Hematology. Notably, the journal is positioned en el Cuartil Q2 para la agencia Scopus (SJR) en la categoría Medicine (Miscellaneous).

From a relative perspective, and based on the normalized impact indicator calculated from the Field Citation Ratio (FCR) of the Dimensions source, it yields a value of: 1.11, which indicates that, compared to works in the same discipline and in the same year of publication, it ranks as a work cited above average. (source consulted: Dimensions Aug 2025)

Specifically, and according to different indexing agencies, this work has accumulated citations as of 2025-08-02, the following number of citations:

  • Scopus: 1

Impact and social visibility

From the perspective of influence or social adoption, and based on metrics associated with mentions and interactions provided by agencies specializing in calculating the so-called "Alternative or Social Metrics," we can highlight as of 2025-08-02:

  • The use, from an academic perspective evidenced by the Altmetric agency indicator referring to aggregations made by the personal bibliographic manager Mendeley, gives us a total of: 6.
  • The use of this contribution in bookmarks, code forks, additions to favorite lists for recurrent reading, as well as general views, indicates that someone is using the publication as a basis for their current work. This may be a notable indicator of future more formal and academic citations. This claim is supported by the result of the "Capture" indicator, which yields a total of: 7 (PlumX).

With a more dissemination-oriented intent and targeting more general audiences, we can observe other more global scores such as:

  • The Total Score from Altmetric: 3.7.
  • The number of mentions on the social network X (formerly Twitter): 3 (Altmetric).

It is essential to present evidence supporting full alignment with institutional principles and guidelines on Open Science and the Conservation and Dissemination of Intellectual Heritage. A clear example of this is:

  • The work has been submitted to a journal whose editorial policy allows open Open Access publication.

Leadership analysis of institutional authors

This work has been carried out with international collaboration, specifically with researchers from: Netherlands.

the author responsible for correspondence tasks has been MUÑOZ CALLEJA, CECILIA.